The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome
Open accessAbstract
It is not understood how immune inflammation influences the pathogenesis of severe acute respiratory syndrome (SARS). One area of strong controversy is the role of interferon (IFN) responses in the natural history of SARS. The fact that the majority of SARS patients recover after relatively moderate illness suggests that the prevailing notion of deficient type I IFN-mediated immunity, with hypercytokinemia driving a poor clinical course, is oversimplified. We used proteomic and genomic technology to systematically analyze host innate and adaptive immune responses of 40 clinically well-described patients with SARS during discrete phases of illness from the onset of symptoms to discharge or a fatal outcome. A novel signature of high IFN-α, IFN-γ, and IFN-stimulated chemokine levels, plus robust antiviral IFN-stimulated gene (ISG) expression, accompanied early SARS sequelae. As acute illness progressed, SARS patients entered a crisis phase linked to oxygen saturation profiles. The majority of SARS patients resolved IFN responses at crisis and expressed adaptive immune genes. In contrast, patients with poor outcomes showed deviated ISG and immunoglobulin gene expression levels, persistent chemokine levels, and deficient anti-SARS spike antibody production. We contend that unregulated IFN responses during acute-phase SARS may culminate in a malfunction of the switch from innate immunity to adaptive immunity. The potential for the use of the gene signatures we describe in this study to better assess the immunopathology and clinical management of severe viral infections, such as SARS and avian influenza (H5N1), is therefore worth careful examination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Atypical IFNmediated immune responses suggest that type I IFN signaling may be important in the pathogenesis of SARS-CoV (21).”
From Into the Eye of the Cytokine Storm (2012) · cites this paper as [21]
In the citing paper
“Gene expression signatures for type I and type II IFN responses in the lungs of SARS patients revealed persistent expression of CXCL10, CCL2, IFNAR1, IFNGR1, and CD58.”
From Into the Eye of the Cytokine Storm (2012) · cites this paper as [21]
Citations
Cites
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
MAQC Consortium, Shi, L., Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1239 · Cited by 2,126
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J. D., Chau, T. N. B., Hoang, D. M., Van Vinh Chau, N., Khanh, T. H., Dong, V. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1477 · Cited by 1,858
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
Wong, C. K., LAM, C. W. K., Wu, A. K. L., Ip, W., Lee, N. L. S., Chan, I., Lit, L. C. W., Hui, D. S. C., Chan, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,270
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Cited by
Sorted by citations
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2588-y · Cited by 2,074
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940
Coronaviruses post-SARS: update on replication and pathogenesis
Perlman, S. M., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,797
A single-cell atlas of the peripheral immune response in patients with severe COVID-19
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martínez-Colón, G. J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0944-y · Cited by 1,493
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. M. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,400
Netland, J., Meyerholz, D. K., Moore, S., Cassell, M., & Perlman, S. (2008) · Journal of Virology · doi:10.1128/jvi.00737-08 · Cited by 1,293
Middle East respiratory syndrome
Zumla, A. I., Hui, D. S. C., & Perlman, S. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,306
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01708 · Cited by 1,094
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhou, Z. L., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.017 · Cited by 980
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park, A., & Iwasaki, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.008 · Cited by 909
Weiss, S. R., & Leibowitz, J. L. (2011) · Advances in virus research · doi:10.1016/b978-0-12-385885-6.00009-2 · Cited by 926
SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS
Oudit, G. Y., Kassiri, Z., Jiang, C., Liu, P. P., Poutanen, S. M., Penninger, J. M., & BUTANY, J. W. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02153.x · Cited by 898
Self-citationChan, J. F., Lau, S. K. P., To, K. K., Cheng, V. C., Woo, P. C. Y., & Yuen, K. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 894
The immune response during acute HIV-1 infection: clues for vaccine development
McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. P., & Haynes, B. F. (2009) · Nature reviews. Immunology · doi:10.1038/nri2674 · Cited by 871
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
Bradley, B. T., Maioli, H., Johnston, R., Chaudhry, I., Fink, S. L., Xu, H., Najafian, B., Deutsch, G. H., Lacy, J. M., Williams, T., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31305-2 · Cited by 826
Stacey, A., Norris, P. J., Li, Q., Haygreen, E. A., Taylor, E., Heitman, J. W., Lebedeva, M., deCamp, A. C., Li, D., Grove, D. I., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01844-08 · Cited by 749
A decade after SARS: strategies for controlling emerging coronaviruses
Graham, R. L., Donaldson, E., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 689
Liu, J., Zheng, X., Tong, Q., Li, W., Wang, B., Sutter, K., Trilling, M., Lu, M., Dittmer, U., & Yang, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25709 · Cited by 629
Nikolich-Zugich, J., Knox, K. S., Rios, C. T., Natt, B., Bhattacharya, D., & Fain, M. J. (2020) · GeroScience · doi:10.1007/s11357-020-00186-0 · Cited by 577
The cGAS–STING pathway drives type I IFN immunopathology in COVID-19
Domizio, J. D., Gulen, M. F., Saidoune, F., Thacker, V. V., Yatim, A., Sharma, K., Nass, T., Guenova, E., Schaller, M., Conrad, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04421-w · Cited by 538
SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling
Miorin, L., Kehrer, T., Sánchez-Aparicio, M. T., Zhang, K., Cohen, P. D., Patel, R. S., Čupić, A., Makio, T., Mei, M., Moreno, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016650117 · Cited by 532
Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477
Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
Major, J., Crotta, S., Llorian, M., McCabe, T. M., Gad, H. H., Priestnall, S. L., Hartmann, R., & Wack, A. (2020) · Science · doi:10.1126/science.abc2061 · Cited by 500
T Cell Responses to Whole SARS Coronavirus in Humans
Li, C. K., Wu, H., Yan, H., Ma, S., Wang, L., Zhang, M., Tang, X., Temperton, N. J., Weiss, R. A., Brenchley, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5490 · Cited by 488
Myocardial injury and COVID-19: Possible mechanisms
Babapoor-Farrokhran, S., Gill, D., Walker, J., Rasekhi, R. T., Bozorgnia, B., & Amanullah, A. M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117723 · Cited by 493
Middle East respiratory syndrome
Memish, Z. A., Perlman, S. M., Kerkhove, M. D. V., & Zumla, A. I. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33221-0 · Cited by 495
Totura, A. L., Whitmore, A. C., Agnihothram, S., Schäfer, A., Katze, M. G., Heise, M. T., & Baric, R. S. (2015) · mBio · doi:10.1128/mbio.00638-15 · Cited by 487
Dysregulation of type I interferon responses in COVID-19
Acharya, D., Liu, G., & Gack, M. U. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0346-x · Cited by 454
Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling
Israelow, B., Song, E., Mao, T., Lu, P., Meir, A., Liu, F., Alfajaro, M. M., Wei, J., Dong, H., Homer, R. J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201241 · Cited by 415
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon
Totura, A. L., & Baric, R. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.04.004 · Cited by 420
Type III interferons disrupt the lung epithelial barrier upon viral recognition
Broggi, A., Ghosh, S., Sposito, B., Spreafico, R., Balzarini, F., Cascio, A. L., Clementi, N., Santis, M. D., Mancini, N., Granucci, F., et al. (2020) · Science · doi:10.1126/science.abc3545 · Cited by 403
Chen, J., Lau, Y. F., Lamirande, E. W., Paddock, C. D., Bartlett, J. H., Zaki, S. R., & Subbarao, K. (2009) · Journal of Virology · doi:10.1128/jvi.01281-09 · Cited by 402
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
Oladunni, F. S., Park, J., Pino, P. A., González, O., Akhter, A., Allué‐Guardia, A., Olmo-Fontánez, A. M., Gautam, S., Garcia‐Vilanova, A., Ye, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19891-7 · Cited by 398
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
Liu, W. J., Zhao, M. J., Liu, K., Xu, K., Wong, G., Tan, W., & Gao, G. F. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.006 · Cited by 400
DeDiego, M. L., Nieto-Torres, J. L., Regla-Nava, J. Á., Jiménez-Guardeño, J. M., Fernández‐Delgado, R., Fett, C., Castaño-Rodríguez, C., Perlman, S. M., & Enjuanes, L. (2013) · Journal of Virology · doi:10.1128/jvi.02576-13 · Cited by 395
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
Bermejo-Martín, J. F., de Lejarazu, R. O., Pumarola, T., Rello, J., Almansa, R., Ramírez, P., Martín‐Loeches, I., Varillas‐Delgado, D., Gallegos, M. C., Arbeloa, C. S., et al. (2009) · Critical Care · doi:10.1186/cc8208 · Cited by 373
Self-citationAboudounya, M. M., & Heads, R. J. (2021) · Mediators of Inflammation · doi:10.1155/2021/8874339 · Cited by 359
Zhao, J., Zhao, J., & Perlman, S. (2010) · Journal of Virology · doi:10.1128/jvi.01049-10 · Cited by 340
Pathophysiology of COVID-19: Why Children Fare Better than Adults?
Dhochak, N., Singhal, T., Kabra, S. K., & Lodha, R. (2020) · The Indian Journal of Pediatrics · doi:10.1007/s12098-020-03322-y · Cited by 358
Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
Smits, S. L., de Lang, A., van den Brand, J. M. A., Leijten, L. M. E., van IJcken, W. F. J., Eijkemans, M. J. C., van Amerongen, G., Kuiken, T., Andeweg, A. C., Osterhaus, A. D. M. E., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000756 · Cited by 332
Lymphopenia in COVID‐19: Therapeutic opportunities
Fathi, N., & Rezaei, N. (2020) · Cell Biology International · doi:10.1002/cbin.11403 · Cited by 324
Molecular pathology of emerging coronavirus infections
Gralinski, L. E., & Baric, R. S. (2014) · The Journal of Pathology · doi:10.1002/path.4454 · Cited by 326
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Luo, W., Li, Y., Jiang, L., Chen, Q., Wang, T., & Ye, D. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.007 · Cited by 294
Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19
Lowery, S. A., Sariol, A., & Perlman, S. M. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.004 · Cited by 303
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
Stebbing, J., Krishnan, V., de Bono, S., Ottaviani, S., Casalini, G., Richardson, P. J., Monteil, V., Lauschke, V. M., Mirazimi, A., Youhanna, S. C., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012697 · Cited by 292
Two distinct immunopathological profiles in autopsy lungs of COVID-19
Nienhold, R., Ciani, Y., Koelzer, V. H., Tzankov, A., Haslbauer, J. D., Menter, T., Schwab, N., Henkel, M., Frank, A., Zsikla, V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18854-2 · Cited by 246
Bermejo-Martín, J. F., González‐Rivera, M., Almansa, R., Micheloud, D., Tedim, A. P., Domínguez‐Gil, M., Resino, S., Martín-Fernández, M., Ryan, P., Pérez‐García, F., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03398-0 · Cited by 264
Self-citationDistinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Faure, E., Poissy, J., Goffard, A., Fournier, C., Kipnis, É., Titécat, M., Bortolotti, P., Martinez, L., Dubucquoi, S., Dessein, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088716 · Cited by 249
Chemokines and chemokine receptors during COVID-19 infection
Khalil, B. A., Elemam, N. M., & Maghazachi, A. A. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.034 · Cited by 248
Dosch, S. F., Mahajan, S. D., & Collins, A. R. (2009) · Virus Research · doi:10.1016/j.virusres.2009.01.005 · Cited by 233
Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections
Nelemans, T., & Kikkert, M. (2019) · Viruses · doi:10.3390/v11100961 · Cited by 228
Rokni, M., Ghasemi, V., & Tavakoli, Z. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2107 · Cited by 226
DeDiego, M. L., Nieto-Torres, J. L., Jiménez-Guardeño, J. M., Regla-Nava, J. Á., Álvarez, E. A., Oliveros, J. C., Zhao, J., Fett, C., Perlman, S. M., & Enjuanes, L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002315 · Cited by 216
Martín‐Loeches, I., Lisboa, T. C., Rhodes, A., Moreno, R. P., Silva, E., Sprung, C. L., Chiche, J., Barahona, D., Villabon, M., Balasini, C., et al. (2010) · Intensive Care Medicine · doi:10.1007/s00134-010-2078-z · Cited by 211
MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV
Sheahan, T. P., Morrison, T. E., Funkhouser, W., Uematsu, S., Akira, S., Baric, R. S., & Heise, M. T. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000240 · Cited by 211
Mubarak, A., Alturaiki, W., & Hemida, M. G. (2019) · Journal of Immunology Research · doi:10.1155/2019/6491738 · Cited by 201
Jiang, Y., Zhao, G., Song, N., Li, P., Chen, Y., Guo, Y., Li, J., Du, L., Jiang, S., Guo, R., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0063-8 · Cited by 195
Wong, L.-Y. R., & Perlman, S. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00656-2 · Cited by 202
Thieme, C. J., Anft, M., Paniskaki, K., Blazquez-Navarro, A., Doevelaar, A., Seibert, F. S., Hoelzer, B., Konik, M. J., Berger, M. M., Brenner, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100092 · Cited by 184
Natural Killer Cells Promote Early CD8 T Cell Responses against Cytomegalovirus
Robbins, S. H., Bessou, G., Cornillon, A., Zucchini, N., Rupp, B., Ruzsics, Z., Sacher, T., Tomasello, E., Vivier, É., Koszinowski, U. H., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030123 · Cited by 198
Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice
Li, K., Wohlford-Lenane, C., Channappanavar, R., Park, J.-E., Earnest, J. T., Bair, T., Bates, A. M., Brogden, K. A., Flaherty, H. A., Gallagher, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619109114 · Cited by 184
Coronavirus virulence genes with main focus on SARS-CoV envelope gene
DeDiego, M. L., Nieto-Torres, J. L., Jiménez-Guardeño, J. M., Regla-Nava, J. Á., Castaño-Rodríguez, C., Fernández‐Delgado, R., Usera, F., & Enjuanes, L. (2014) · Virus Research · doi:10.1016/j.virusres.2014.07.024 · Cited by 174
Gene Expression Analysis of Host Innate Immune Responses during Lethal H5N1 Infection in Ferrets
Cameron, C., Cameron, M. J., Bermejo-Martín, J. F., Ran, L., Xu, L., Turner, P. V., Ran, R., Danesh, A., Yuan, F., Chan, P.-K., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00691-08 · Cited by 179
Self-citationKelvin, A. A., Banner, D., Silvi, G., Moro, M. L., Spataro, N., Gaibani, P., Cavrini, F., Pierro, A. M., Rossini, G., Cameron, M. J., et al. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001279 · Cited by 175
Self-citationRockx, B., Baas, T., Zornetzer, G. A., Haagmans, B. L., Sheahan, T. P., Frieman, M. B., Dyer, M. D., Teal, T. H., Proll, S. C., van den Brand, J. M. A., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00127-09 · Cited by 176
Host adaptive immunity deficiency in severe pandemic influenza
Bermejo-Martín, J. F., Martín‐Loeches, I., Rello, J., Antón, A., Almansa, R., Xu, L., López–Campos, G., Pumarola, T., Ran, L., Ramírez, P., et al. (2010) · Critical Care · doi:10.1186/cc9259 · Cited by 174
Self-citationvan den Brand, J. M. A., Haagmans, B. L., van Riel, D. A. J., Osterhaus, A. D. M. E., & Kuiken, T. (2014) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2014.01.004 · Cited by 161
Frieman, M. B., Chen, J., Morrison, T. E., Whitmore, A., Funkhouser, W., Ward, J. M., Lamirande, E. W., Roberts, A., Heise, M., Subbarao, K., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000849 · Cited by 158
Is asthma protective against COVID‐19?
Carli, G., Cecchi, L., Stebbing, J., Parronchi, P., & Farsi, A. (2020) · Allergy · doi:10.1111/all.14426 · Cited by 166
Immune responses during COVID-19 infection
Melenotte, C., Silvin, A., Goubet, A., Lahmar, I., Dubuisson, A., Zumla, A. I., Raoult, D., Merad-Boudia, M., Gachot, B., Henon, C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1807836 · Cited by 167
Interferon and cytokine responses to SARS-coronavirus infection
Thiel, V., & Weber, F. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.01.001 · Cited by 150
Pathogenesis of Middle East respiratory syndrome coronavirus
van den Brand, J. M. A., Smits, S. L., & Haagmans, B. L. (2014) · The Journal of Pathology · doi:10.1002/path.4458 · Cited by 154
Zhao, J., Zhao, J., van Rooijen, N., & Perlman, S. M. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000636 · Cited by 151
Regla-Nava, J. Á., Nieto-Torres, J. L., Jiménez-Guardeño, J. M., Fernández‐Delgado, R., Fett, C., Castaño-Rodríguez, C., Perlman, S. M., Enjuanes, L., & DeDiego, M. L. (2015) · Journal of Virology · doi:10.1128/jvi.03566-14 · Cited by 153
Innate immune modulation by RNA viruses: emerging insights from functional genomics
Katze, M. G., Fornek, J. L., Palermo, R. E., Walters, K., & Korth, M. J. (2008) · Nature reviews. Immunology · doi:10.1038/nri2377 · Cited by 150
Intranasal Treatment with Poly(I·C) Protects Aged Mice from Lethal Respiratory Virus Infections
Zhao, J., Wohlford-Lenane, C., Zhao, J., Fleming, E., Lane, T. E., McCray, P. B., & Perlman, S. M. (2012) · Journal of Virology · doi:10.1128/jvi.01410-12 · Cited by 145
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.120.315894 · Cited by 138
Netland, J., DeDiego, M. L., Zhao, J., Fett, C., Álvarez, E. A., Nieto-Torres, J. L., Enjuanes, L., & Perlman, S. M. (2010) · Virology · doi:10.1016/j.virol.2010.01.004 · Cited by 134
Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses
Bordt, E. A., Shook, L. L., Atyeo, C. G., Pullen, K. M., Guzman, R. M. D., Meinsohn, M.-C., Chauvin, M. Y., Fischinger, S., Yockey, L. J., James, K. E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi7428 · Cited by 135
Paračková, Z., Zentsová, I., Bloomfield, M., Vrabcová, P., Smetanová, J., Klocperk, A., Mesežnikov, G., Méndez, L. F. C., Vymazal, T., & Šedivá, A. (2020) · Cells · doi:10.3390/cells9102206 · Cited by 129
Mohapatra, R. K., Pintilie, L., Kandi, V., Sarangi, A. K., Das, D., Sahu, R., & Perekhoda, L. O. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13761 · Cited by 132
T cell immunobiology and cytokine storm of COVID‐19
Luo, X., Zhu, Y., Mao, J., & Du, R. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12989 · Cited by 127
Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System
Lima, M., Siokas, V., Aloizou, A., Liampas, I., Mentis, A. A., Tsouris, Z., Papadimitriou, A., Mitsias, P. D., Tsatsakis, A. M., Bogdanos, D. P., et al. (2020) · Current Treatment Options in Neurology · doi:10.1007/s11940-020-00647-z · Cited by 129
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
Ceribelli, A., Motta, F., Santis, M. D., Ansari, A. A., Ridgway, W. M., Gershwin, M. E., & Selmi, C. F. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102442 · Cited by 125
Scheuplein, V., Seifried, J., Malczyk, A. H., Miller, L., Höcker, L., Vergara‐Alert, J., Dolnik, O., Zielecki, F., Becker, B., Spreitzer, I., et al. (2015) · Journal of Virology · doi:10.1128/jvi.03607-14 · Cited by 123
Transcriptomic correlates of organ failure extent in sepsis
Almansa, R., Heredia‐Rodríguez, M., Gómez‐Sánchez, E., Andaluz‐Ojeda, D., Iglesias, V., Rico, L., Ortega, A., Gómez‐Pesquera, E., Liu, P., Aragón, M. F., et al. (2014) · Journal of Infection · doi:10.1016/j.jinf.2014.12.010 · Cited by 122
Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection
Bermejo-Martín, J. F., Almansa, R., Menéndez, R., Méndez, R., Kelvin, D. J., & Torres, A. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.02.029 · Cited by 120
Self-citationMuñoz, F. M., Cramer, J. P., Dekker, C. L., Dudley, M. Z., Graham, B. S., Gurwith, M., LAW, B. J., Perlman, S. M., Polack, F. P., Spergel, J. M., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.055 · Cited by 119
Approaches and Challenges in SARS-CoV-2 Vaccine Development
Dagotto, G., Yu, J., & Barouch, D. H. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.08.002 · Cited by 103
Network-based analysis of comorbidities risk during an infection: SARS and HIV case studies
Moni, M. A., & Lió, P. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-333 · Cited by 106
Rosa, B. A., Ahmed, M., Singh, D. K., Choreño-Parra, J. A., Cole, J., Jiménez-Álvarez, L. A., Rodríguez-Reyna, T. S., Singh, B., Gonzalez, O., Carrion, R., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01829-4 · Cited by 106
Reverse Genetics of SARS-Related Coronavirus Using Vaccinia Virus-Based Recombination
van den Worm, S. H. E., Eriksson, K., Zevenhoven-Dobbe, J. C., Weber, F., Züst, R., Kuri, T., Dijkman, R., Chang, G., Siddell, S. G., Snijder, E. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032857 · Cited by 106
Molecular Biology of the SARS-Coronavirus
Lal, S. K. (2010) · Springer eBooks · doi:10.1007/978-3-642-03683-5 · Cited by 103
Metadata
- Authors
- Cameron, M. J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J. F., Cameron, C. M., Muller, M. P., Gold, W. L., Richardson, S. E., Poutanen, S. M., Willey, B. M., DeVries, M. E., Fang, Y., Seneviratne, C., Bosinger, S. E., Persad, D., Wilkinson, P., Greller, L. D., Somogyi, R., Humar, A., Keshavjee, S., Louie, M., Loeb, M. B., Brunton, J., McGeer, A. J., the Canadian SARS Research Network, & Kelvin, D. J.
- Affiliations
- University Health Network (CA)
- University of Valladolid, Valladolid, Spain
- Mount Sinai Hospital (CA)
- University of Toronto (CA)
- University Health Network, Toronto, Ontario, Canada
- Centre Hospitalier de l’Université de Montréal (CA)
- Biosystemix, Sydenham, Ontario, Canada
- Provincial Laboratory of Public Health (CA)
- McMaster University (CA)
- ORCID
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2007-08-15
- Volume
- 81
- Issue
- 16
- Pages
- 8692-8706
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC1951379
- OpenAlex
- W2049902839
- Cited by
- 386
- References
- 59
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 8 · 2023: 14 · 2022: 31 · 2021: 71 · 2020: 121 · 2019: 5 · 2018: 1 · 2017: 8 · 2016: 7 · 2015: 10 · 2014: 11 · 2013: 10 · 2012: 10
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS, interferon, type I interferon, interferon-stimulated genes, interferon-alpha, interferon-gamma, chemokines, innate immunity, adaptive immunity, immunopathology, SARS-CoV, spike antibodies, immunoglobulin genes, gene expression signatures, cytokine storm, H5N1 avian influenza, viral pathogenesis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Viral, Antibody Formation, Female, Humans, Immunity, Innate, Interferons, Male, Middle Aged, Gene Expression, Cytokines, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, Proteomics, Severe Acute Respiratory Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review